Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Targeted Oncology|July 17, 2020
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i>-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
Future Oncology (London, England)|March 20, 2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community settingGiuseppe Procopio, Lisa Derosa, Angela Gernone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, Cosimo Rasola, Riccardo Lobefaro, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 studyValentina Guarneri, Franco Bassan, Vittorina Zagonel, et al.
Urologic Oncology|April 25, 2015
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and youngerOrazio Caffo, Cinzia Ortega, Giuseppe Di Lorenzo, et al.
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
European Urology|December 3, 2014
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre StudyOrazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Pageof 7